TRADES
Latest Trades
194
results found
FUND
DATE
ACTION
TICKER
COMPANY
SHARES
% of ETF
ARKF 28 Apr 2022 Buy TDOC TELADOC HEALTH INC 29,830 0.0795
ARKG 28 Apr 2022 Buy TDOC TELADOC HEALTH INC 130,094 0.1377
ARKK 28 Apr 2022 Buy TDOC TELADOC HEALTH INC 386,712 0.1252
ARKW 28 Apr 2022 Buy TDOC TELADOC HEALTH INC 63,029 0.1046
ARKF 26 Apr 2022 Buy TDOC TELADOC HEALTH INC 5,015 0.0247
ARKG 26 Apr 2022 Buy TDOC TELADOC HEALTH INC 22,072 0.0423
ARKK 26 Apr 2022 Buy TDOC TELADOC HEALTH INC 63,879 0.0379
ARKW 26 Apr 2022 Buy TDOC TELADOC HEALTH INC 10,597 0.0314
ARKF 25 Apr 2022 Buy TDOC TELADOC HEALTH INC 2,224 0.0110
ARKG 25 Apr 2022 Buy TDOC TELADOC HEALTH INC 9,808 0.0190
ARKK 25 Apr 2022 Buy TDOC TELADOC HEALTH INC 28,191 0.0171
ARKW 25 Apr 2022 Buy TDOC TELADOC HEALTH INC 4,717 0.0143
ARKF 8 Feb 2022 Buy TDOC TELADOC HEALTH INC 5,589 0.0247
ARKG 8 Feb 2022 Buy TDOC TELADOC HEALTH INC 26,829 0.0473
ARKK 8 Feb 2022 Buy TDOC TELADOC HEALTH INC 69,273 0.0406
ARKW 8 Feb 2022 Buy TDOC TELADOC HEALTH INC 12,127 0.0331
ARKF 14 Jan 2022 Buy TDOC TELADOC HEALTH INC 22,943 0.1013
ARKG 14 Jan 2022 Buy TDOC TELADOC HEALTH INC 50,210 0.0941
ARKK 14 Jan 2022 Buy TDOC TELADOC HEALTH INC 173,708 0.0999
ARKW 14 Jan 2022 Buy TDOC TELADOC HEALTH INC 46,472 0.1177
ARKF 13 Jan 2022 Buy TDOC TELADOC HEALTH INC 5,700 0.0245
ARKG 13 Jan 2022 Buy TDOC TELADOC HEALTH INC 13,400 0.0243
ARKK 13 Jan 2022 Buy TDOC TELADOC HEALTH INC 43,800 0.0238
ARKW 13 Jan 2022 Buy TDOC TELADOC HEALTH INC 10,100 0.0246
ARKF 10 Jan 2022 Buy TDOC TELADOC HEALTH INC 13,200 0.0546
ARKG 10 Jan 2022 Buy TDOC TELADOC HEALTH INC 31,800 0.0553
ARKK 10 Jan 2022 Buy TDOC TELADOC HEALTH INC 101,100 0.0577
ARKW 10 Jan 2022 Buy TDOC TELADOC HEALTH INC 23,400 0.0547
ARKF 5 Jan 2022 Buy TDOC TELADOC HEALTH INC 6,900 0.0280
ARKG 5 Jan 2022 Buy TDOC TELADOC HEALTH INC 17,000 0.0290
ARKK 5 Jan 2022 Buy TDOC TELADOC HEALTH INC 51,500 0.0277
ARKW 5 Jan 2022 Buy TDOC TELADOC HEALTH INC 12,300 0.0286
ARKF 4 Jan 2022 Buy TDOC TELADOC HEALTH INC 29,000 0.1236
ARKF 3 Jan 2022 Buy TDOC TELADOC HEALTH INC 8,500 0.0364
ARKG 3 Jan 2022 Buy TDOC TELADOC HEALTH INC 19,500 0.0368
ARKK 3 Jan 2022 Buy TDOC TELADOC HEALTH INC 37,481 0.0218
ARKW 3 Jan 2022 Buy TDOC TELADOC HEALTH INC 14,500 0.0363
ARKK 31 Dec 2021 Buy TDOC TELADOC HEALTH INC 28,000 0.0158
ARKK 30 Dec 2021 Buy TDOC TELADOC HEALTH INC 2,056 0.0012
ARKF 29 Dec 2021 Buy TDOC TELADOC HEALTH INC 10,000 0.0392
ARKG 29 Dec 2021 Buy TDOC TELADOC HEALTH INC 22,500 0.0397
ARKK 29 Dec 2021 Buy TDOC TELADOC HEALTH INC 97,300 0.0531
ARKW 29 Dec 2021 Buy TDOC TELADOC HEALTH INC 17,000 0.0387
ARKF 28 Dec 2021 Buy TDOC TELADOC HEALTH INC 14,500 0.0574
ARKG 28 Dec 2021 Buy TDOC TELADOC HEALTH INC 33,000 0.0572
ARKK 28 Dec 2021 Buy TDOC TELADOC HEALTH INC 50,318 0.0272
ARKW 28 Dec 2021 Buy TDOC TELADOC HEALTH INC 24,900 0.0565
ARKK 27 Dec 2021 Sell TDOC TELADOC HEALTH INC 67,719 0.0366
ARKW 27 Dec 2021 Sell TDOC TELADOC HEALTH INC 53,340 0.1219
ARKK 20 Dec 2021 Buy TDOC TELADOC HEALTH INC 29,000 0.0167
ARKK 7 Dec 2021 Buy TDOC TELADOC HEALTH INC 63,567 0.0383
ARKG 6 Dec 2021 Buy TDOC TELADOC HEALTH INC 54,879 0.1000
ARKK 6 Dec 2021 Buy TDOC TELADOC HEALTH INC 110,215 0.0600
ARKF 29 Nov 2021 Buy TDOC TELADOC HEALTH INC 1,400 0.0051
ARKG 29 Nov 2021 Buy TDOC TELADOC HEALTH INC 2,650 0.0049
ARKK 29 Nov 2021 Buy TDOC TELADOC HEALTH INC 8,800 0.0050
ARKW 29 Nov 2021 Buy TDOC TELADOC HEALTH INC 2,300 0.0050
ARKF 22 Nov 2021 Buy TDOC TELADOC HEALTH INC 13,500 0.0471
ARKG 22 Nov 2021 Buy TDOC TELADOC HEALTH INC 28,000 0.0494
ARKK 22 Nov 2021 Buy TDOC TELADOC HEALTH INC 86,500 0.0486
ARKW 22 Nov 2021 Buy TDOC TELADOC HEALTH INC 23,000 0.0489
ARKF 19 Nov 2021 Buy TDOC TELADOC HEALTH INC 5,500 0.0205
ARKG 19 Nov 2021 Buy TDOC TELADOC HEALTH INC 10,500 0.0199
ARKK 19 Nov 2021 Buy TDOC TELADOC HEALTH INC 30,500 0.0184
ARKW 19 Nov 2021 Buy TDOC TELADOC HEALTH INC 8,100 0.0185
ARKF 18 Nov 2021 Buy TDOC TELADOC HEALTH INC 40,224 0.1508
ARKG 18 Nov 2021 Buy TDOC TELADOC HEALTH INC 78,216 0.1448
ARKK 18 Nov 2021 Buy TDOC TELADOC HEALTH INC 234,681 0.1413
ARKW 18 Nov 2021 Buy TDOC TELADOC HEALTH INC 62,024 0.1416
ARKF 5 Nov 2021 Buy TDOC TELADOC HEALTH INC 58,951 0.2499
ARKG 5 Nov 2021 Buy TDOC TELADOC HEALTH INC 133,829 0.2576
ARKK 5 Nov 2021 Buy TDOC TELADOC HEALTH INC 111,833 0.0750
ARKW 5 Nov 2021 Buy TDOC TELADOC HEALTH INC 92,968 0.2438
ARKK 4 Nov 2021 Buy TDOC TELADOC HEALTH INC 242,352 0.1650
ARKK 3 Nov 2021 Buy TDOC TELADOC HEALTH INC 4,660 0.0032
ARKG 29 Oct 2021 Buy TDOC TELADOC HEALTH INC 60,632 0.1221
ARKF 28 Oct 2021 Buy TDOC TELADOC HEALTH INC 93,448 0.4091
ARKG 28 Oct 2021 Buy TDOC TELADOC HEALTH INC 64,400 0.1344
ARKK 28 Oct 2021 Buy TDOC TELADOC HEALTH INC 456,665 0.3134
ARKW 28 Oct 2021 Buy TDOC TELADOC HEALTH INC 90,039 0.2482
ARKK 18 Oct 2021 Buy TDOC TELADOC HEALTH INC 100 0.0001
ARKK 15 Oct 2021 Buy TDOC TELADOC HEALTH INC 48,448 0.0315
ARKF 12 Oct 2021 Buy TDOC TELADOC HEALTH INC 4,358 0.0179
ARKG 12 Oct 2021 Buy TDOC TELADOC HEALTH INC 83,532 0.1618
ARKK 12 Oct 2021 Buy TDOC TELADOC HEALTH INC 110,791 0.0738
ARKF 11 Oct 2021 Buy TDOC TELADOC HEALTH INC 37,682 0.1513
ARKK 11 Oct 2021 Buy TDOC TELADOC HEALTH INC 173,944 0.1154
ARKG 8 Oct 2021 Buy TDOC TELADOC HEALTH INC 12,496 0.0235
ARKK 8 Oct 2021 Buy TDOC TELADOC HEALTH INC 81,569 0.0528
ARKG 7 Oct 2021 Buy TDOC TELADOC HEALTH INC 81,837 0.1600
ARKW 7 Oct 2021 Buy TDOC TELADOC HEALTH INC 55,191 0.1400
ARKF 6 Oct 2021 Buy TDOC TELADOC HEALTH INC 41,819 0.1600
ARKW 6 Oct 2021 Buy TDOC TELADOC HEALTH INC 31,367 78.2900
ARKK 5 Oct 2021 Buy TDOC TELADOC HEALTH INC 154,175 0.1021
ARKK 23 Sep 2021 Buy TDOC TELADOC HEALTH INC 256,100 0.1671
ARKG 22 Sep 2021 Buy TDOC TELADOC HEALTH INC 49,572 0.0868
ARKK 22 Sep 2021 Buy TDOC TELADOC HEALTH INC 133,063 0.0869
ARKG 21 Sep 2021 Buy TDOC TELADOC HEALTH INC 90,387 0.1594
ARKW 21 Sep 2021 Buy TDOC TELADOC HEALTH INC 98,667 0.2557
ARKF 2 Sep 2021 Buy TDOC TELADOC HEALTH INC 17,173 0.0700
Latest Blogs
ARK by Cathie Wood is still suffering a year after its apex.

Cathie Wood's flagship exchange-traded fund hit an all-time high in February of this year. Her preferred disruptive-tech chasing strategy may still be in for a lot of suffering after a year and a 53 percent fall.

After a dramatic decline last month, the ARK Innovation ETF (ticker: ARKK) has steadied off - it's practically flat in February – but the headwinds surrounding its speculative growth picks are just becoming more vital. Many businesses that thrived during the pandemic are being hammered by the economic reopening, not only because yields are rising as investors prepare for the US Federal Reserve to raise interest rates, which is terrible news for unprofitable businesses, but also because the economic reopening is hammering many of the businesses that thrived during the pandemic.

Roku, Teladoc, and Zoom, all winners in the work-from-home era, have had their stock prices plummet by as much as 74% in the past year.

Short bets against ARK, according to IHS Markit data, hit a fresh high of 11.4 percent of outstanding shares this week. The Tuttle Capital Short Innovation ETF (SARK), which beats the ARK, now has assets worth more than $US300 million ($416 million).

"Those equities are supported by speculation, and speculation pays less well when the Fed raises rates," said Brent Schutte, chief investment strategist at Northwestern Mutual Wealth Management Co. "Much of what's happening in the market reminds me of what happened in the late 1990s when market segments were bid up to levels based on future assumptions."

Because its price chart resembles that of the Nasdaq index of technology businesses from more than two decades ago, analogies to that period and the dot-com implosion that followed are becoming more common in discussions of ARK.

"Today marks the 253rd trading day from ARK's all-time high," Jessica Rabe, co-founder of DataTrek Research, wrote in a Tuesday note, "while the Nasdaq was down 60% from its dot-com bubble top on the same day in 2001."

"If 2000/2001 analog holds, we should see ARK continuing to fall over the following three weeks. The Nasdaq dropped 18.7% in the next 16 trading days "recent."

Net flows are positive.

The better news for investors and Ms. Wood is that there may be some immediate respite. The Nasdaq rose 41% in six weeks in 2001 before falling.

The ARK Investment Management did not respond to a request for comment.

Most of ARK's $US15 billion asset loss has been attributed to bad performance, a plus for the company. Since the fund achieved an intraday high of $US159.70 a year ago this week, investors have withdrawn only around $US465 million, and ARK's net flows this year are positive despite a more than 20% drop.

This exceptional loyalty prevents a worsening situation and allows Wood's approach to recovering. The star fund manager has consistently emphasized that her funds have a five-year investment horizon and that she believes in many good options.

Mr. Schutte, on the other hand, says the drop is understandable because several of the company's biggest bets, such as Teladoc and Zoom, are becoming less significant as COVID-19 approaches.

"During the pandemic, there were a lot of questions about what would happen to society and how we'd go about our lives," he added.

"You drew in new investors who wanted to know "what are the upcoming themes I should invest in?" I believe you got a washout of it as well."

On Friday, Cathie Wood sold $148.9 million worth of Palantir stock, halving her exposure.

Ark Investment Management, run by Cathie Wood, sold more Palantir Technologies Inc PLTR -6.39 percent shares on Friday, cutting its stake in the Peter Thiel-backed company.

According to Friday's closing price, the famous investment management firm sold 13.5 million shares of the big data company, valued at $148.9 million.

Palantir's stock fell 6.4 percent to $11.02 per share on Friday. The stock has lost 16% of its value in the last week.

Before Friday's trade, Ark Invest held 25.53 million shares in Palantir, suggesting that the famous stock picker had trimmed over 52 percent of its total keeping a day later.

After the business disclosed lower-than-expected fourth-quarter earnings before the market opened on Thursday, Ark Invest, located in St. Petersburg, California, dumped shares in Palantir for the second time.

The software firm, well-known for its work with government organizations, posted earnings of 2 cents per share, falling short of the analyst consensus of 4 cents. The company recorded quarterly revenues of $432.87 million, higher than the $417.69 million predicted by analysts.

Palantir's stock had been sold for 4.77 million shares by the investment firm the day before.

All six of Ark Invest's active exchange-traded funds own Palantir stock, including the flagship Ark Innovation ETF ARKK -4.88 percent.

Before the recent sell-off, Ark Invest had been stockpiling Palantir shares for months.

Cathie Wood appeared on television to defend her ARK funds' dismal performance. It didn't go quite as planned.

The Ark Innovation ETF (ARKK), Cathie Wood's flagship fund, is down 30% year to date and more volatile than almost any other fund on the market. On CNBC's Halftime Report, Wood jumped at the chance to defend the fund and its deflated price, which is currently $68.80, down from $155 a year ago.

"We've seen a significant decline," Wood said, adding, "We feel innovation is at bargain basement zone." Even though her ETF was underperforming, she emphasized that her companies were still "very inexpensive" and that the current fund loss was temporary. When the call's 40 free minutes were finished, Zoom gave her an extra 10 minutes to complete the interview.

Having Zoom check to see whether she was "running out of time?" Wood, who has been aggressively buying up shares in Zoom and other IT firms that have fallen from their pandemic highs, was unhappy. Zoom, like Wood's other significant tech holdings, Teladoc Health, Roku, and Roblox, is down 20% to 40% year to date as investors worry about rising interest and inflation rates.

However, a significant chunk of the interview was devoted to a personal assault on Cathie Wood, who was named the most excellent stock picker in 2020 by Bloomberg's then-Editor-in-Chief Matthew Winkler after correctly forecasting that Tesla will one day be valued at more than $1 trillion.

Wood bluntly ignored Tuttle Capital Management's Short Innovation ETF (SARK), which tracks the inverse performance of ARKK using swaps contracts for the sole purpose of betting against Cathie Wood's selections. "They're not conducting any research." She explained, "All they're doing is shorting innovation."

Of course, SARK is betting against Cathie Woods, not on innovation. "Well, we stand for invention," Wood responded. The SARK ETF has gained 55 percent since its debut, whereas the ARKK ETF has declined by 42 percent.

Tuttle Capital Management CEO Matthew Tuttle chimed in on the SARK ETF, calling it a "tool" for investors. According to SARK, "to convey a negative view of the market, innovative enterprises, the current rising rate environment, or a [specific] portfolio manager if they wish." "It's un-American not to have options in the marketplace," Tuttle told Insider on Thursday.

In any event, Wood is making progress. Her main concern currently is bearish calls on her ETF. "Our major concern is that our investors convert temporary losses into long-term losses," Wood continued.